Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-phase-ii-study-of-intravenous-exatecan-mesylate-dx-8951f-d18sQAEwZW
References (38)
-
E. Rowinsky, T. Johnson, C. Geyer, L. Hammond, S. Eckhardt, R. Drengler, L. Smetzer, J. Coyle, J. Rizzo, G. Schwartz, A. Tolcher, D. Hoff, R. Jager (2000)
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
C. Verschraegen, E. Gupta, E. Loyer, J. Kavanagh, A. Kudelka, R. Freedman, C. Edwards, N. Harris, M. Steger, V. Steltz, B. Giovanella, J. Stehlin (1999)
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.Anti-cancer drugs, 10 4
-
J. Berek, K. Bertelsen, A. Bois, M. Brady, J. Carmichael, E. Eisenhauer, M. Gore, S. Grénman, T. Hamilton, S. Hansen, P. Harper, G. Horvath, S. Kaye, H. Lück, B. Lund, W. Mcguire, J. Neijt, R. Ozols, M. Parmar, M. Piccart-Gebhart, R. Rijswijk, P. Rosenberg, G. Rustin, C. Sessa, J. Thigpen, C. Tropé, M. Tuxen, I. Vergote, J. Vermorken, P. Willemse (1999)
Advanced epithelial ovarian cancerAnnals of Oncology, 10
-
(1993)
Antitumor activity of DX-8951, a new camptothecin derivative (abstract) -
A. Gordon, M. Bookman, W. Huinink, M. Gore, H. Malmström, J. Krebs, S. Fields (1997)
Pooled analysis of patients (PTS) treated with topotecan (T) after progression or failure on platinum (PLAT) and paclitaxel (P) -
S. Green, G. Weiss (1992)
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 10
-
(1997)
ADAPT-II users manual -
(2000)
A phase I pharmacokinetic (PK) study of the camptothecin (CPT) analog DX-8951f (exatecan mesylate): escalating infusion duration and dose -
Y. Kawato, H. Terasawa (1997)
2 Recent Advances in the Medicinal Chemistry and Pharmacology of CamptothecinProgress in Medicinal Chemistry, 34
-
E. Kumazawa, T. Jimbo, Y. Ochi, A. Tohgo (1998)
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude miceCancer Chemotherapy and Pharmacology, 42
-
M. Ishii, M. Iwahana, I. Mitsui, M. Minami, S. Imagawa, A. Tohgo, A. Ejima (2000)
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6Anti-Cancer Drugs, 11
-
C. Holschneider, J. Berek (2000)
Ovarian cancer: epidemiology, biology, and prognostic factors.Seminars in surgical oncology, 19 1
-
R. Lawrence, E. Izbicka, R. Jager, A. Tohgo, G. Clark, S. Weitman, E. Rowinsky, D. Hoff (1999)
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.Anti-cancer drugs, 10 7
-
(2000)
DX8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies -
H. Minami, H. Fujii, T. Igarashi, K. Itoh, K. Tamanoi, T. Oguma, Y. Sasaki (2001)
Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
-
(1999)
Phase I and pharmacokinetic (PK) study of DX-8951f, a novel camptothecin analog, given as 30 minute infusion daily for 5 days -
D. Marsden, M. Friedlander, N. Hacker (2000)
Current management of epithelial ovarian carcinoma: a review.Seminars in surgical oncology, 19 1
-
N. Joto, M. Ishii, M. Minami, H. Kuga, I. Mitsui, A. Tohgo (1997)
DX‐8951F, a water‐soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN‐38‐resistant variantInternational Journal of Cancer, 72
-
(1982)
Multicompartment models. In: Swarbrick J (ed) Pharmacokinetics -
T. Oguma, Y. Ohshima, M. Nakaoka (2000)
Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection.Journal of chromatography. B, Biomedical sciences and applications, 740 2
-
S. Takiguchi, E. Kumazawa, T. Shimazoe, A. Tohgo, A. Kono (1997)
Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude MiceJapanese Journal of Cancer Research : Gann, 88
-
M. Wall, M. Wani (1996)
Camptothecin. Discovery to clinic.Annals of the New York Academy of Sciences, 803
-
(1994)
High potency of a camptothecin derivative DX-8951 might be attributed to good membrane permeability (abstract) -
(1997)
Recent advances in the medicinal chemistry and pharmacology of camptothecin. In: Ellis GP, Luscombe DK (eds) Progress in medicinal chemistry -
(1984)
The calculation and interpretation of survival curves -
M. Royce, P. Hoff, P. Dumas, Y. Lassere, J. Lee, J. Coyle, M. Ducharme, R. Jager, R. Pazdur (2001)
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 5
-
(1995)
IT2S user s guide. State University of New York at Buffalo, Buffalo -
M. Maliepaard, M. Gastelen, A. Tohgo, Frederick Hausheer, R. Waardenburg, L. Jong, D. Pluim, J. Beijnen, J. Schellens (2001)
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 4
-
(1982)
Multicompartment models -
I. Mitsui, E. Kumazawa, Y. Hirota, M. Aonuma, M. Sugimori, S. Ohsuki, K. Uoto, A. Ejima, H. Terasawa, Keiki Sato (1995)
A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivoJapanese Journal of Cancer Research : Gann, 86
-
S. Sharma, N. Kemeny, G. Schwartz, D. Kelsen, E. O’Reilly, D. Ilson, J. Coyle, R. Jager, M. Ducharme, S. Kleban, E. Hollywood, L. Saltz (2001)
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 12
-
(1995)
Antitumor effect of DX - 8951 , a new camptothecin derivative , in various murine models ( abstract ) -
G. Rustin, A. Nelstrop, P. McClean, M. Brady, W. McGuire, W Hoskins, H. Mitchell, H. Lambert (1996)
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
-
R. Simon (1989)
Optimal two-stage designs for phase II clinical trials.Controlled clinical trials, 10 1
-
K. Yamaoka, T. Nakagawa, T. Uno (1978)
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 6
-
M. Wall, M. Wani (1996)
Discovery to Clinic aAnnals of the New York Academy of Sciences, 803
-
A. Hattum, H. Pinedo, H. Schlüper, C. Erkelens, A. Tohgo, E. Boven (2002)
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.Biochemical pharmacology, 64 8
-
J. Berek, K. Bertelsen, A. Bois, M. Brady, J. Carmichael, E. Eisenhauer, M. Gore, S. Grénman, T. Hamilton, S. Hansen, P. Harper, G. Horvath, S. Kaye, H. Lück, B. Lund, W. McGuire, J. Neijt, R. Ozols, M. Parmar, M. Piccart-Gebhart, R. Rijswijk, P. Rosenberg, G. Rustin, C. Sessa, J. Thigpen, C. Tropé, M. Tuxen, I. Vergote, J. Vermorken, P. Willemse (1999)
Advanced epithelial ovarian cancer: 1998 consensus statements.Annals of oncology : official journal of the European Society for Medical Oncology, 10 Suppl 1
- Publisher
- Springer Journals
- Copyright
- Copyright © 2003 by Springer-Verlag
- Subject
- Medicine
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-003-0696-7
- pmid
- 14586557
- Publisher site
- See Article on Publisher Site
Abstract
DX-8951f administered parenterally as a single agent daily at a dose of either 0.5 or 0.3 mg/m 2 per day for 5 days is feasible in patients with advanced ovarian, tubal and peritoneal cancer resistant to platinum, taxane and topotecan. Although no responses were observed, a significant number of patients had stable disease with a decrease in CA-125 levels. In this heavily pretreated population, DX-8951f has clinically relevant hematologic and gastrointestinal toxicities in about 25% of patients. DX-8951 appeared to have linear pharmacokinetic characteristics on the basis of multiple administrations.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Jan 1, 2004